Temasek and HighLight Capital Invested ~USD150m in Hong Kong’s Viva Shanghai
Temasek and HighLight Capital invested CNY1.1b (~USD150m) in Viva Shanghai, a subsidiary of Hong Kong-based drug discovery platform Viva Biotech Holdings.
Temasek and HighLight Capital invested CNY1.1b (~USD150m) in Viva Shanghai, a subsidiary of Hong Kong-based drug discovery platform Viva Biotech Holdings.